Article
Source: Campus Sanofi

T1 Edition Junior Study

Author : Sanofi

Editorial Team

All relevant safety information about adverse reactions, precautions, and relevant contraindications can be found on the product page HERE.

Edition Junior

Download this clinical summary to read about the benefits of Toujeo® Insulin Glargine 300U/ml in children and adolescents from the age of 6 years in this randomised trial. Edition Junior was a 6 month long, open-label, double arm, parallel group, non-inferiority study in 463 children with T1DM. The aim of the study was to demonstrate non-inferiority of Toujeo^® vs insulin glargine 100 U/mL from baseline to Week 26.

Download

See More From Science

Toujeo

Toujeo^® is indicated as treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.

More About Toujeo

Patient Materials

Find resources and support for your patients who have been prescribed Toujeo^®. This section will help you to help your patients understand the basis of living and staying well with diabetes and how to have a a positive start and experience with Toujeo^®.

Access Patient Materials